Connect with us

NEWS

Cannabis Sales Tracked With Faster Heart Hospitalizations in the West

Recreational cannabis sales in the Western U.S. tracked with faster heart admissions, but the study measured a law rather than any patient’s cannabis use.

Published

on

Recreational marijuana legalization in the Western U.S. tracked with faster hospital admissions for atrial fibrillation, heart failure and heart attacks, a BMJ Open study of 50,042,564 records found. The paper, posted Oct. 22, 2026, compared 13 Western states with the rest of the country from 2012 through 2018.

Lead author Samuel D. Slavin of Boston University and Harvard T.H. Chan School of Public Health, with colleagues at Beth Israel Deaconess Medical Center, did not test whether any patient had used cannabis. They tested whether years of legal recreational sales moved population hospital rates.

Three Heart Diagnoses Rose Faster After Legal Sales

The team pulled discharge diagnoses from the National Inpatient Sample, the largest all-payer inpatient database, which covers about 97% of the U.S. population through a 20% sample of more than 7 million stays a year. They tracked six heart and vessel diagnoses, plus cannabis-related codes as a positive control and two unrelated diagnoses as a check.

Before stores opened, admission rates for those heart diagnoses were lower in the West than elsewhere. After legal sales began in 2014, the West climbed faster. Fully adjusted, each year of legal sales was tied to a 2.3% rise in the atrial fibrillation rate, a 3.7% rise in heart failure, and a 3.1% rise in heart attacks, against regions that had not opened stores.

YEARLY CHANGE IN HOSPITAL RATES AFTER LEGAL SALES

Diagnosis Change per year of sales 95% CI Threshold
Cannabis-related diagnoses +13.8% 1.066 to 1.214 Rose
Atrial fibrillation or flutter +2.3% 1.010 to 1.035 Rose
Heart failure +3.7% 1.029 to 1.046 Rose
Heart attack +3.1% 1.014 to 1.048 Rose
Ischemic stroke +1.1% 0.999 to 1.024 No clear change
Venous blood clots +0.9% 0.999 to 1.020 No clear change
Ventricular tachycardia +1.9% 0.993 to 1.046 No clear change
Urinary stones +0.6% 0.986 to 1.027 No clear change
Opioid-related diagnoses -3.4% 0.927 to 1.006 No clear change

Stroke, clots and ventricular tachycardia leaned up, but their intervals still included no change. Kidney stones and opioid diagnoses, the fake controls, did not rise with sales years. That pattern is the paper’s main claim: common heart admissions moved with the law, while the checks did not.

The Study Tracked a Law, Not a Patient

Most cannabis-and-heart papers ask whether people who use cannabis later have worse hearts, then spend pages worrying that those people also smoke tobacco, drink, or already hurt. Slavin’s group flipped the question. Recreational sales started in the Western census region in January 2014, almost five years before other regions, so the country itself became the comparison.

The nationwide difference-in-differences analysis coded exposure as years of legal recreational sales, zero outside the West for the whole window. Models adjusted for age, sex, income, and race or ethnicity. Cannabis diagnosis codes, the positive control, rose 13.8% with each year of sales, which is the paper’s evidence that the law actually moved cannabis-related hospital coding.

The National Inpatient Sample only supports regional comparisons, so the whole West was treated as exposed from Colorado’s first sale. Idaho and other Western states that had not opened stores still sat in the treatment group. The authors wrote that this misspecification likely pushed results toward no effect, not away from it, and that state files were incomplete and too costly. They also could not see illegal markets or how people consumed the plant.

Western inpatients were younger than those elsewhere, with a median age of 51 versus 55, and more often from higher-income ZIP codes (26% versus 19%). They were 57% female in both regions, and 43% of Western patients were non-white compared with 33% elsewhere. The extra admissions did not come from an older ward on its face. They came from a region that had opened stores.

How Cannabis Can Stress a Heart

The paper’s physiology file is short and old: THC turns up the sympathetic nervous system, raises heart rate and the heart’s oxygen need, and lifts blood pressure when a person is lying down. The authors also pointed to clotting and inflammatory effects on vessel lining and platelets. CBD, they noted, may lower heart rate and blood pressure, which is why a store shelf is not one drug.

WHAT THC DOES IN THE BODY

  • Nerve tone: THC activates sympathetic drive and damps the parasympathetic brake, so the pulse climbs.
  • Oxygen demand: A faster, harder beat makes the heart muscle hungrier for blood at the same moment vessels may be less helpful.
  • Clotting and fire: THC has been tied to platelet activation and to inflammatory stress on the endothelium.
  • Receptor split: Harm is largely framed through cannabinoid receptor 1, while CBD leans toward other paths.

A January 2025 review by Mark Chandy and colleagues in Nature Reviews Cardiology tied cannabis to heart attack, stroke, arrhythmia and heart failure through CB1-mediated oxidative stress and inflammation, and flagged synthetic products as a separate, sharper risk. The American Heart Association’s 2020 scientific statement had already told clinicians that cannabis offers few cardiac benefits and several cardiac concerns, often tied to how it is taken.

Individual-level work sits beside the new law study rather than repeating it. In a 2024 Journal of the American Heart Association paper, Abra M. Jeffers, Stanton Glantz, Amy L. Byers and Salomeh Keyhani assessed 434,104 U.S. adults. Daily users, 4% of that sample, had 25% higher odds of heart attack and 42% higher odds of stroke than non-users after tobacco and other risks were held, a dose pattern that also appeared for daily cannabis use and heart attack among people who had never smoked tobacco. Those are odds among users, not hospital-rate changes after a sales law, and the two should not be mashed into one percentage.

While an observational study cannot prove causality, our findings point to potential adverse effects of recreation legalisation on population health.

Samuel D. Slavin and colleagues, BMJ Open, October 2026

Older Adults Arrived After the Study Ended

The discharge window closed in December 2018. The fastest growth in cannabis use since then has been among people whose hearts are already less forgiving. Benjamin H. Han of the University of California San Diego, with Joseph Palamar of NYU Grossman School of Medicine, used the National Survey on Drug Use and Health to track past-month cannabis use among older adults in a June 2, 2025, JAMA Internal Medicine research letter.

Among 15,689 adults age 65 or older, past-month use rose from 4.8% in 2021 to 5.2% in 2022 and to 7.0% in 2023. Han said that in 2006 and 2007, less than 1% of older adults had used cannabis in the past year. The new users were not the stereotype of a young recreational buyer. Gains were steepest among college graduates, married people, and households earning $75,000 or more, and among people already living with chronic disease.

PAST-MONTH CANNABIS USE AT AGE 65 AND OLDER

  • All older adults: Use rose from 4.8% in 2021 to 7.0% in 2023.
  • Heart conditions: Use among older adults with heart disease rose from 2.8% to 6.5%.
  • High income: Use among those earning $75,000 or more rose from 4.2% to 9.1%.
  • COPD: Use among older adults with chronic obstructive pulmonary disease rose from 6.4% to 13.5%.

Those shares describe who is using cannabis, not how often they land in a heart ward. They still change the reading of Slavin’s file. If a sales law already tracked with faster atrial fibrillation, heart failure and heart attack admissions while Western inpatients were younger than the national mix, a later wave of 65-and-older customers is the part of the story the 2012-2018 records could not contain.

Holdout States Inside the Treatment Group

Census maps are clumsy tools for a store-by-store market. Colorado began legal recreational sales in January 2014, Washington followed in July 2014, and one additional Western state opened each year through 2018. By January 2018, 79.3% of the Western population lived in a state with legal sales, and 98.6% lived in a sales state or a state that bordered one. Massachusetts opened in late November 2018, with a volume the authors called negligible before year-end, so the rest of the country stayed coded as unexposed.

HOW THE WESTERN SALES WINDOW OPENED

  1. January 2012: The National Inpatient Sample window opens, two years before the first legal recreational sale.
  2. January 2014: Colorado begins legal recreational cannabis sales, the start of Western exposure in the model.
  3. July 2014: Washington begins legal sales, and additional Western states follow one a year through 2018.
  4. January 2018: 79.3% of the Western population lives in a sales state, and 98.6% live in or next to one.
  5. November 2018: Massachusetts opens, with negligible volume before December, when the study window shuts.

The 13-state Western list is Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming. Several of those states had not opened recreational stores by 2018, yet every Western discharge sat on the exposed side of the ledger. Anyone looking for a clean on/off switch will not find one in this design, and the authors said so.

What the Discharge Files Could Not Show

Slavin, Amy R. Mahar, Eric A. Secemsky, Robert W. Yeh and Murray A. Mittleman call this the first look at recreational cannabis laws and specific cardiovascular hospitalizations. Prior legalization studies, they wrote, leaned on psychiatric diagnoses, substance use, emergency visits and traffic crashes. The size of the file is the strength. The blindness of a discharge code is the limit.

WHAT WE KNOW

  • The three diagnoses: Atrial fibrillation, heart failure and heart attack admission rates rose faster in the West after sales began, after age, sex, income and race were held.
  • The positive control: Cannabis-related hospital codes rose with years of sales, which is the paper’s check that the law moved cannabis in the file.
  • The fake controls: Kidney stones and opioid diagnoses did not rise with sales years.

WHAT IS UNCONFIRMED

  • Any given patient: The records do not show whether the person in the bed had used cannabis, or how.
  • The holdout West: States without stores still sat inside the exposed region, a blur the authors say likely weakened the result.
  • Today’s user mix: The file ends in 2018, before the later jump in use among people 65 and older, including people with heart disease.

A difference-in-differences model can still be fooled by any West-versus-rest shift that started in 2014 for other reasons, from coding changes to other public-health trends. The authors followed Agency for Healthcare Research and Quality rules on survey weights and on the ICD-9 to ICD-10 switch, and they still cannot name a joint in a single chart.

The Sales Map Grew After the Records Closed

As of June 2025, the researchers noted, medical cannabis was legal in 41 states, three territories and the District of Columbia, and recreational use was legal in 24 states, three territories and the District of Columbia. That is a wider map than the one that generated these discharges, and it is the map hospitals are working from now.

The authors asked for a cautious approach to new sales laws, paired with collection of cardiovascular outcomes, and they warned that similar laws abroad could raise heart-care use. They did not call for repeal, and they did not claim a courtroom level of proof. They reported that a first-wave sales region, scored from the year stores opened, admitted people faster for three common heart diagnoses than regions that had not yet opened stores, in a file that closed before the oldest customers arrived in force.

Disclaimer: This article is news reporting on a published observational study and related research, and it is for information only. It is not medical advice, a diagnosis, or a recommendation to start, stop, or change cannabis, CBD, or any heart medicine. Readers with heart disease, arrhythmia, or other cardiovascular conditions should talk with a qualified physician or cardiologist before changing a cannabis or medication routine. Figures and legal counts reflect the cited papers and databases as of their publication dates and may change as new studies and state laws appear.

Harry is the editor of CBD STRAINS ONLY, his own independent publication about CBD, hemp and cannabis strains, the products made from them and the rules that govern their sale. He has been a journalist for ten years, first reporting and then editing, and the bulk of that time has gone to this beat. Product coverage rests on the certificate of analysis: he reads the third party lab reports for cannabinoid content, terpene profile, residual solvents, pesticides and heavy metals, compares the numbers with what the label claims, and names the gap when there is one. Strain write-ups draw on breeder records, seed bank listings and published genetics work rather than on forum lore. Legal thresholds for THC in hemp, licensing rules and labelling requirements are quoted from the statute or regulation itself, and every figure is checked before publication. The site keeps a public corrections policy. None of this is medical advice; cannabis law differs by jurisdiction, and readers with a health condition should consult a clinician before using any product. Mail to Harry goes to support@cbdstrainsonly.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending